Also known as: nonsense mutation DMD
Duchenne muscular dystrophy is a progressive X-linked recessive neuromuscular disorder caused by pathogenic variants in the DMD gene, leading to dysfunctional or absent dystrophin. It usually presents in early childhood and predominantly affects males, with progressive muscle weakness and degeneration. It is one of the most common inherited neuromuscular disorders of childhood.
A U.S. appeals court revived Regenxbio’s patent suit against Sarepta, holding the asserted gene-therapy host cell claims are markedly different from anything occurring in nature.
Sarepta Therapeutics said it will announce first quarter 2026 financial results. The event will be webcast on its investor relations website, with a replay archived for one year.
India's rare disease treatment funding fell to Rs 32.73 crore in 2025-26 from Rs 82.87 crore a year earlier, while several Centres of Excellence reported unspent balances. In Madhya Pradesh, concerns were also raised over the absence of dedicated rare disease centres in most state-run medical colleges.
Mesoblast received FDA clearance for a registrational DMD trial of remestemcel-L-rknd, while Satellos began dosing boys in the Phase 2 BASECAMP study of SAT-3247. The studies are enrolling children ages 5-9 and 7-9, respectively.
Duchenne muscular dystrophy care is shifting toward broader multidisciplinary management and closer attention to early pathology, biomarkers, and treatment timing. Clinicians described an expanding treatment landscape and identified neurology, cardiology, pulmonary, and endocrinology as core priorities.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
Diamyd Medical anticipates March 2026 interim results from its Phase 3 diabetes trial that could support a BLA pathway. Capricor Therapeutics awaits an August 2026 FDA decision on its Duchenne muscular dystrophy treatment BLA. Bicara Therapeutics prepares for Phase 3 study initiation of its oncology candidate toward future BLA submission.
Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.
The FDA has lifted a Complete Response Letter and resumed review of Capricor Therapeutics' Biologics License Application for deramiocel, setting a PDUFA date of August 22nd. The company ended 2025 with $318M in cash.
Scientists have developed two breakthrough approaches to dramatically enhance gene editing and mRNA therapy delivery: a simple amino acid supplement that increases CRISPR efficiency to nearly 90 percent, and a self-replicating CRISPR system that spreads between cells like a virus.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07542314 |
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting |
NOT_YET_RECRUITING | PHASE4 |
| NCT07287189 |
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients |
RECRUITING | PHASE2 |
| NCT07209332 |
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07172737 |
Investigation of the Effects of Functional Inspiratory Muscle Training Applied With Tele-Rehabilitation on Respiratory and Functional Parameters and Quality of Life in Children With Duchenne Muscular Dystrophy: Randomized Controlled Study |
COMPLETED | NA |
| NCT07160634 |
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) |
RECRUITING | PHASE3 |
| NCT06868784 |
Investigation of the Relationship Between Executive Functions and Occupational Performance of Children With Duchenne Muscular Dystrophy |
ENROLLING_BY_INVITATION | |
| NCT06861270 |
Estimation of Non-Reimbursable Costs for Patients With Duchenne Muscular Dystrophy in France |
RECRUITING | |
| NCT06817382 |
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD) |
RECRUITING | PHASE1 |
| NCT06769633 |
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old |
RECRUITING | PHASE2 |
| NCT06756633 |
Respiratory Functions, Thoracoabdominal Movements and Exercise Capacity in Neuromuscular Diseases |
RECRUITING |
